RNAC logo

CARTESIAN THERAPEUTICS INC

RNACNASDAQ
🏆 #3669 by market capUS Equity
$692.36▲ $37.11 (+5.36%)
Simulated price
🔔
Track RNAC
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.4%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$218M
Small Cap
📈Revenue Growth (YoY)
-92.8%
Declining
📊Gross Margin
-766.4%
Thin
💵FCF Margin
-5291.5%
Thin
⚖️P/S Ratio
147.4x
Expensive
Otter Score
56
Weak
No chart data available for RNAC.

Trading Snapshot

Day Range
$681.72 – $695.32
52-Week Range
$5.60 – $11.00
Volume
$5.47B
Avg Volume
$7.01B
Shares Outstanding
29.4M
Next Earnings
Oct 21, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$387,460
P/E Ratio
-1.2
P/S Ratio
147.4x
EPS (TTM)
$-5.22
Dividend Yield
0.00%
Dilution (1yr)
+0.3%

Why Investors Own RNAC

  • ✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 60% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RNAC logo

CARTESIAN THERAPEUTICS INC

RNAC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3M▼ −92.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$87M▲ +97.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$79M▲ +142.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
26.0M▲ +0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$112M▼ −$86M YoY
StockOtter · stockotter.space

About CARTESIAN THERAPEUTICS INC

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$754.00
▲ +8.9% Upside
High Target$928.74
Low Target$621.10
Based on 39 analysts

Latest News & Updates

🚀
CNBC·2h ago

CARTESIAN THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift RNAC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

CARTESIAN THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.